Evolving challenges in medical device evaluation

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 1, 2008, Pages 1-6

  Holmes Jr , David R ^a   Firth, Brian G ^b   Hodgson, Patricia K ^c   Rihal, Charanjit S ^a   Wood, Douglas L ^a   Cohen, David J ^d  

^a MAYO CLINIC   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CARDIOVASCULAR DISEASE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HEALTH CARE COST; INTERVENTION STUDY; MEDICAL INSTRUMENTATION; QUALITY CONTROL; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; STANDARD;

EID: 47549102608     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21541     Document Type: Review

References (39)

1. Baim DS, Mehran R, Kereiakes DJ, et al. Postmarket surveillance for drug-eluting coronary stents: A comprehensive approach. Circulation 2006;113:891-897.
2. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 2005;45:1206-1212.
3. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: Design concepts and issues-The encounters of academic consultants in statistics. Stat Med 2006;25:1097-1099.
4. Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1193-1200.
5. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-591.
6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
9. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113.
10. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
11. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
12. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-514.
13. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816-2821.
14. Kuntz RE, Safian RD, Levine MJ, Reis GJ, Diver DJ, Baim DS. Novel approach to the analysis of restenosis after the use of three new coronary devices. J Am Coll Cardiol 1992;19:1493-1499.
15. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation 1993;88:1310-1323.
16. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-2089.
17. Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005;111:321-327.
18. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Inform J 2001;35:435-449.
19. Hauck WW, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Inform J 1999;33:109-118.
20. Lemos PA, Mercado N, van Domburg RT, Kuntz RE, O'Neill WW, Serruys PW. Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 2004;110:3199-3205.
21. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006;48:2440-2447.
22. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
23. Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998; 97:322-331.
24. Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Intern Med 1986;104:345-348.
25. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-16.
26. Pocock SJ, Henderson RA, Seed P, Treasure T, Hampton JR. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) trial. Circulation 1996;94:135-142.
27. Bowen J, Hopkins R, He Y, et al. Systematic review and cost-effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario: Interim report. Report no. HTA002-0512, prepared for the Ontario Ministry of Health and Long-term Care. Hamilton, ON, Canada: Program for Assessment of Technology in Health, McMaster University, December 2005:170. Available at http:// www.path-hta.ca/DESreport.pdf. Accessed on September 7, 2007.
28. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-721.
29. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43: 513-518.
30. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001;104:3039-3045.
31. Cohen DJ, Cosgrove RS, Berezin RH, Teirstein PS, Leon MB, Kuntz RE;Gamma-l Investigators. Cost-effectiveness of γ radiation for treatment of in-stent restenosis: Results from the γ-1 trial. Circulation 2002;106:691-697.
32. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:253-261.
33. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-681.
34. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110:1226-1230.
35. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32-36.
36. Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. Am Heart J 2005;149:434-443.
37. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol 2001; 3:113-119.
38. Greenberg D, Bakhai A, Neumann PJ, Cohen DJ. Willingness to pay for avoiding coronary restenosis and repeat revascularization: Results from a contingent valuation study. Health Pol 2004;70:207-216.
39. National Institute for health and Clinical Excellence. Ischaemic heart disease-Coronary artery stents (review): Appraisal consultation document. Available at http://guidance.nice.org.uk/page. aspx?o=445413. Accessed on October 19, 2007.